Regulatory PathRegulatory requirements compared

Active substances

Calcium carbonate + Sodium alginate + Sodium bicarbonate

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
GAVISCON DOUBLE ACTION CHEWABLE TABLET250,187.5,106.5 mg,mg,mgChewable tablet · Oral use32 BlisterSAR 21.10NCE · OTCRECKITT BENCKISER HEALTHCARE INTERNATIONALValid
GAVISCON DOUBLE ACTION CHEWABLE TABLET250,187.5,106.5 mg,mg,mgChewable tablet · Oral use16 BlisterSAR 10.55NCE · OTCRECKITT BENCKISER HEALTHCARE INTERNATIONALValid
GAVISCON DOUBLE ACTION ORAL SUSPENSION500,325,213 mg,mg,mgOral suspension · Oral use1 BottleSAR 25.10Generic · OTCRECKITT BENCKISER HEALTHCARE INTERNATIONALValid
GAVISCON DOUBLE ACTION ORAL SUSPENSION500,325,213 mg,mg,mgOral suspension · Oral use1 BottleSAR 12.55Generic · OTCRECKITT BENCKISER HEALTHCARE INTERNATIONALValid
GAVISCON ORIGINAL ANISEED ORAL SUSP500,267,160 mg,mg,mgOral suspension · Oral use1 BottleSAR 15.20Generic · OTCRECKITT BENCKISERValid
GAVISCON PEPPERMINT CHEWABLE TABLETS250,133.50,80 mg,mg,mgChewable tablet · Oral use16 BlisterSAR 9.60Generic · OTCRECKITT BENCKISERValid
GAVISCON PEPPERMINT LIQUID500,267,160 mg,mg,mgOral suspension · Oral use1 BottleSAR 15.20Generic · OTCRECKITT BENCKISERValid
GAVISCON COOL CHEWABLE TABLETS250,133.5,80 mg,mg,mgChewable tablet · Oral use16 BlisterSAR 8.00Generic · OTCRECKITT BENCKISER HEALTHCARE COMPANYWithdrawn by MAH · Not Marketed
Indications — CHI Daman Drug Formulary

ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.